Northwire Canada EditionFriday, November 6, 2026
Sign inSubscribe
Northwire
⌕
Gold 4,113.50 +1.0% Silver 52.38 +0.2% Copper 6.21 −3.4% Oil 90.52 +2.7% Palladium 1,034.00 +3.1% GRZ 5.25 −8.7% TNGD 5.20 +2.0% IMG 24.46 −0.1% III 6.05 −2.6% SCMI 0.900 −5.3% TSK 0.810 −1.2% MEK 0.040 +0.0% GAU 2.99 +2.0% SVM 11.69 −3.5% NGEX 20.70 −4.6% WPM 185.96 +1.2% ETG 2.58 −7.9% CG 29.87 −0.2% EMO 0.190 −2.6% TUF 0.660 −5.7% APMI 0.095 −13.6% Gold 4,113.50 +1.0% Silver 52.38 +0.2% Copper 6.21 −3.4% Oil 90.52 +2.7% Palladium 1,034.00 +3.1% GRZ 5.25 −8.7% TNGD 5.20 +2.0% IMG 24.46 −0.1% III 6.05 −2.6% SCMI 0.900 −5.3% TSK 0.810 −1.2% MEK 0.040 +0.0% GAU 2.99 +2.0% SVM 11.69 −3.5% NGEX 20.70 −4.6% WPM 185.96 +1.2% ETG 2.58 −7.9% CG 29.87 −0.2% EMO 0.190 −2.6% TUF 0.660 −5.7% APMI 0.095 −13.6%
Earnings

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Rakovina Therapeutics Confirms Accelerating Burn Rate and Critical Cash Position Despite Financing

By The Northwire Desk — AI Analysis Apr 30, 2026 · 17:10 RKV · 0.115 Rakovina Therapeutics Inc.
Executive Summary
  • Financial Results: Rakovina reported a full-year net loss of $8.68M for FY 2025, more than doubling from $4.07M in FY 2024. Q4 net loss was $1.89M.
  • Cash Position: As of December 31, 2025, cash and equivalents stood at only $298,758 with a working capital deficit of $2.15M.
  • Financing Activity: Closed a non-brokered private placement of convertible debenture units for $1M gross proceeds on March 5, 2026. Restructured approximately $1.59M in existing debentures via share settlements and replacement debentures.
  • Pipeline Progress: Three AI-powered programs (kt-5000, kt-3283, kt-2000) are advancing toward milestones in 2026. IND-enabling studies for kt-5000 targeted for H2 2026.
  • Corporate Updates: Completed a 10-to-1 share consolidation on June 24, 2025. New CEO Kim Oishi appointed in January 2026.
Material Impact
  • Cash Runway Risk: The cash balance of $298k at year-end combined with an $8.68M annual burn rate indicates a critical liquidity gap that requires immediate future financing to reach IND milestones in H2 2026.
  • Dilution Pressure: Recent financing involved issuing warrants ($1M raised = ~2M warrants) and share settlements for debt, increasing the fully diluted share count and potential selling pressure at $0.20 strike price.
  • Loss Acceleration: The doubling of net losses year-over-year signals increased R&D spend without corresponding revenue, raising concerns about capital efficiency.
  • Market Reaction: Stock price has declined significantly from July 2025 highs ($0.82) to current levels ($0.11), reflecting market pricing in the high burn rate and dilution risk.
RKV · Price
Company Overview
  • Company: Rakovina Therapeutics Inc., focused on AI-driven drug discovery for oncology.
  • Flagship Project: kt-5000 (ATR-mTOR inhibitor). Designed using Variational AI's Enki platform to target PTEN-deficient cancers with CNS penetration.
  • Secondary Projects: kt-3283 (PARP/HDAC inhibitor) utilizing NanoPalm LNP formulation; kt-2000 (PARP inhibitor).
  • Development Stage: Preclinical. IND-enabling studies targeted for H2 2026.
Read the original news release →

More from Rakovina Therapeutics Inc.

Jun 01, 2026 · 17:00

Rakovina Cuts Costs and Restructures Debt, But Pre-Revenue Burn Rate Demands Immediate Capital Infusion

Earnings Apr 22, 2026 · 04:00

AI-Driven Oncology Pipeline Validates Preclinical Efficacy

Other Mar 23, 2026 · 04:00

Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum

Other Mar 12, 2026 · 15:28

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

Financings Mar 05, 2026 · 20:50

Rakovina closes $1-million debenture unit financing

Financings Mar 05, 2026 · 20:06

Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

Financings